Hansoh MET Combination Improves PFS After EGFR Therapy
Hansoh disclosed a statistically significant PFS result for dalmelitinib plus aumolertinib versus platinum chemotherapy in a China Phase III trial of EGFR-mutant, MET-amplified NSCLC after EGFR-TKI failure. Absolute median benefit was 1.8 months; overall…
